Grechko, Nikolay
Skarbova, Viera
Tomaszewska-Kiecana, Monika http://orcid.org/0000-0001-5271-9998
Ramlau, Rodryg http://orcid.org/0000-0002-3199-2298
Centkowski, Piotr
Drew, Yvette http://orcid.org/0000-0001-6676-9224
Dziadziuszko, Rafal http://orcid.org/0000-0001-8080-9843
Zemanova, Milada http://orcid.org/0000-0002-1904-1035
Beltman, Jeri
Nash, Eileen
Habeck, Jenn
Liao, Mingxiang http://orcid.org/0000-0003-1853-1419
Xiao, Jim http://orcid.org/0000-0003-3632-2012
Funding for this research was provided by:
Clovis Oncology, Inc.
Article History
Received: 3 December 2020
Accepted: 14 April 2021
First Online: 28 April 2021
Change Date: 6 May 2021
Change Type: Update
Change Details: The original version is updated due to replacement of the supplemental figure from .eps file to PDF version.
Declarations
:
: N. Grechko, J. Beltman, E. Nash, J. Habeck, M. Liao, and J.J. Xiao are employees of Clovis Oncology and may own stock or have stock options in that company. Y. Drew is an employee of Newcastle University and has received royalty payments from Newcastle for her involvement in the development of rucaparib; she has served as an advisory board member and received research funding from Clovis Oncology. R. Dziadziuszko has received renumeration from AstraZeneca, Foundation Medicine, MSD, Novartis, Pfizer, Roche, Seattle Genetics, and Takeda. The other authors declare no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Independent Ethics Committees (IEC).
: Written informed consent was obtained from all individual participants included in the study before participation.